Characteristics and circumstances of death related to new psychoactive stimulants and hallucinogens in Australia.


Journal

Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587

Informations de publication

Date de publication:
01 11 2019
Historique:
received: 23 05 2019
revised: 30 07 2019
accepted: 30 07 2019
pubmed: 24 9 2019
medline: 18 7 2020
entrez: 24 9 2019
Statut: ppublish

Résumé

New psychoactive stimulants and hallucinogens comprise a range of "designer drugs" that have risen to prominence in the 21 All cases in which new psychoactive stimulants were a mechanism contributory to death were retrieved from the National Coronial Information System (2000-2017). Information was collected on cause of death, demographics, drug use history, circumstances of death, toxicology and major organ pathology. 82 cases were identified. The mean age was 30.7yrs and 86.6% were male. Circumstances of death were: accidental drug toxicity (59.8%), traumatic accident (15.9%), suicide (12.2%) and natural disease (2.4%). The most common clinical presentation observed proximal to death was delirium (26.8%). Delirium was mostly frequently observed after phenethylamine consumption (72.2%). The most common cardiovascular diagnosis at autopsy was replacement fibrosis, indicative of previous ischemia (10.5%). New psychoactive stimulants and hallucinogens detected in toxicology were: cathinones (75.7%), phenethylamines (22.0%) and piperazines (6.1%). Other substances were present in 83.5% of cases, most commonly established controlled psychostimulants (58.2%). Acute toxicity was the most common cause of death, but more than a third of deaths were due to trauma. Cathinones were the most commonly detected of the new psychoactive stimulants and hallucinogens. Delirium was the most frequently reported clinical sign proximal to death and was strongly associated with the phenethylamines.

Sections du résumé

BACKGROUND
New psychoactive stimulants and hallucinogens comprise a range of "designer drugs" that have risen to prominence in the 21
METHODS
All cases in which new psychoactive stimulants were a mechanism contributory to death were retrieved from the National Coronial Information System (2000-2017). Information was collected on cause of death, demographics, drug use history, circumstances of death, toxicology and major organ pathology.
RESULTS
82 cases were identified. The mean age was 30.7yrs and 86.6% were male. Circumstances of death were: accidental drug toxicity (59.8%), traumatic accident (15.9%), suicide (12.2%) and natural disease (2.4%). The most common clinical presentation observed proximal to death was delirium (26.8%). Delirium was mostly frequently observed after phenethylamine consumption (72.2%). The most common cardiovascular diagnosis at autopsy was replacement fibrosis, indicative of previous ischemia (10.5%). New psychoactive stimulants and hallucinogens detected in toxicology were: cathinones (75.7%), phenethylamines (22.0%) and piperazines (6.1%). Other substances were present in 83.5% of cases, most commonly established controlled psychostimulants (58.2%).
CONCLUSIONS
Acute toxicity was the most common cause of death, but more than a third of deaths were due to trauma. Cathinones were the most commonly detected of the new psychoactive stimulants and hallucinogens. Delirium was the most frequently reported clinical sign proximal to death and was strongly associated with the phenethylamines.

Identifiants

pubmed: 31546120
pii: S0376-8716(19)30333-3
doi: 10.1016/j.drugalcdep.2019.107556
pii:
doi:

Substances chimiques

Central Nervous System Stimulants 0
Designer Drugs 0
Hallucinogens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107556

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Shane Darke (S)

National Drug and Alcohol Research Centre, University of New South Wales, NSW, 2052, Australia; School of Psychology, University of Wollongong, Northfields Ave Wollongong, NSW, 2522, Australia. Electronic address: s.darke@unsw.edu.au.

Johan Duflou (J)

National Drug and Alcohol Research Centre, University of New South Wales, NSW, 2052, Australia; Sydney Medical School, University of Sydney, NSW, 2006, Australia; School of Psychology, University of Wollongong, Northfields Ave Wollongong, NSW, 2522, Australia.

Amy Peacock (A)

National Drug and Alcohol Research Centre, University of New South Wales, NSW, 2052, Australia; School of Psychology, University of Wollongong, Northfields Ave Wollongong, NSW, 2522, Australia.

Michael Farrell (M)

National Drug and Alcohol Research Centre, University of New South Wales, NSW, 2052, Australia; School of Psychology, University of Wollongong, Northfields Ave Wollongong, NSW, 2522, Australia.

Julia Lappin (J)

National Drug and Alcohol Research Centre, University of New South Wales, NSW, 2052, Australia; School of Psychiatry, University of New South Wales, NSW, 2052, Australia; School of Psychology, University of Wollongong, Northfields Ave Wollongong, NSW, 2522, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH